Drugs used to treat diabetes and obesity, or GLP-1 (Glucagon-like peptide-1), will be a significant growth driver for ...

Following a downturn in M&A in 2024, the pharma and life sciences industry can expect to see a busier year in 2025.

Vertex Pharmaceuticals Incorporated looks set for two new drug approvals in early 2025. Click here to read an analysis of ...

As Donald J. Trump gradually fills out his cabinet, the President-elect’s latest pick could bode well for biopharma business ...

By far, the largest acquisition of 2024 was Novo Holdings' yet-to-be-closed buyout of manufacturer Catalent at $16.5 billion.

Cardiff Oncology's promising Phase 2 trial data for Onvansertib in colorectal cancer may lead to accelerated FDA approval, ...

The United States Patent and Trademark Office (USPTO)’s withdrawal of its proposed terminal disclaimer rule is seen as a ...

Donald Trump and Robert F. Kennedy Jr. hosted the chief executives of Pfizer, Eli Lilly and PhRMA for dinner at Mar-a-Lago.

After celebrating Donald Trump’s nomination of Robert F. Kennedy Jr. to lead the Department of Health and Human Services (HHS ...

Monday, the state of Arkansas claimed final victory in its legal battle with Big Pharma when the Supreme Court denied a ...

The president-elect and his choice to run the Department of Health and Human Services dined with pharmaceutical executives ...